3M CompanyMMM
Recorded

3M Company Investor update

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Chinmay TrivediSVP of Investor Relations and Financial Planning and Analysis

Good morning, everyone. Thank you for joining us today. Yesterday, we announced that we have reached a settlement to resolve the personal injury claims at the center of the aqueous film-forming foam multi-district litigation, or the AFFF MDL, that is pending in the federal court in South Carolina. On today's call, we will highlight the key terms of the agreement and its financial implications. The eight-K filing includes the settlement agreement itself, and I would refer you to that filing for the specific terms of the agreement. Please note that the charge associated with the settlement will be reflected as a special item when arriving at 3M's adjusted results. Please also note that there is no change to our financial guidance for the full year 2026 and the framework for 2027 that was previously provided on October 20th, 2026.

Chinmay TrivediSVP of Investor Relations and Financial Planning and Analysis

With me today are Bill Brown, our Chairman and Chief Executive Officer, Kevin Rhodes, our Chief Legal Affairs Officer, and Anurag Maheshwari, our Chief Financial Officer. Bill, Kevin, and Anurag will make some formal comments, then we will take your questions on topics exclusively referenced in today's call. I would request that you limit your question to one per participant to keep the call timely and efficient. The press release and the slide presentation accompanying this call are posted on the homepage of our investor relations website at 3M.com. Before we begin, please take a moment to read the forward-looking statement. During today's call, we will make predictive statements that reflect our current views about 3M's future performance and financial results. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties.

Chinmay TrivediSVP of Investor Relations and Financial Planning and Analysis

Item 1A of our most recent Form 10-K lists some of the most important risk factors that could cause actual results to differ from our expectations. With that, please turn to slide three, and I will turn it over to Bill.

Bill BrownChairman and CEO

Bill? Thank you, Chinmay, and good morning, everyone.

Bill BrownChairman and CEO

Let me start by framing where we are in our PFAS litigation docket. There are three broad areas that have been the most active. The first is the public water suppliers, the subject of our 2023 settlement. The second is the state attorneys general cases, which we continue to manage. Last year, we announced our settlement with the state of New Jersey that was approved by the court earlier this year. The third is personal injury, the subject of the agreement we announced yesterday. This settlement represents a significant milestone in addressing the personal injury litigation, and more broadly, another significant step forward in managing 3M's legacy PFAS matters. We set out to accomplish three goals in getting to a resolution.

Bill BrownChairman and CEO

One, achieve a total dollar amount and payment schedule consistent with our cash generation capacity and broader capital allocation priorities and commitments. Two, obtain broad risk mitigation in the personal injury docket. Three, have the MDL court defer consideration of further proceedings as to 3M for a period of time, which we expect the court will do as part of this settlement. With this agreement, we accomplished all three goals. The process over the past year positioned us to resolve the core of the personal injury docket on terms we view as favorable. Over the course of this year, the MDL court followed a process to require the filing and vetting of claims to establish whether each of the plaintiffs was entitled to litigate in the MDL.

Bill BrownChairman and CEO

We have previously noted that, according to official court reports, approximately 15,250 cases are pending in the MDL, and we have stated that many of those cases have multiple plaintiffs. Following the vetting process, we now estimate that approximately 115,000 to 120,000 plaintiffs will be able to participate in this settlement. This agreement addresses a material risk for the company and is supported by the Plaintiffs' Executive Committee and the AFFF MDL court. As Kevin will explain in a moment, it provides a framework for addressing both existing and future personal injury claims. Importantly, we structured the $7.35 billion nominal commitment to be paid over nine years, with significant payments not beginning until 2028. We will take a pre-tax charge of $5.8 billion, representing the present value of future payments, which we will exclude from our non-GAAP results.

Bill BrownChairman and CEO

These cash outflows are aligned with our other known obligations, allowing us to continue investing in the growth of the company, consistent with our broader capital allocation priorities. Going forward, we expect the AFFF MDL proceedings to take into account the significant work 3M has done to resolve both the PWS claims and the personal injury claims, and we anticipate the MDL court to issue an order deferring consideration of further proceedings as to 3M while we implement the settlement. Finally, let me put this announcement in context. Resolving this major piece of our PFAS docket allows the team to bring even greater focus to our enterprise priorities and commitments to our employees, customers, and shareholders. This settlement is consistent with our commitments to drive long-term shareholder value that we made at our 2025 Investor Day, our guidance for the remainder of 2026, and our framework leading into 2027.

Bill BrownChairman and CEO

To walk you through the specifics of the agreement and how it mitigates material risk to 3M, let me turn it over to Kevin.

Kevin RhodesChief Legal Affairs Officer

Thank you, Bill. Please turn to slide four. This settlement is designed to meaningfully reduce 3M's current and future risk. The agreement does that in three primary ways. One, the vast majority of personal injury plaintiffs are eligible to participate. Two, it includes financial incentives to drive broad plaintiff participation. And three, it addresses the risk of remaining and future claims. First, the vast majority of personal injury plaintiffs are eligible for this settlement. As Bill noted, we have completed the court-ordered vetting process. About 40,000 claims have been dismissed without prejudice. We expect about 115,000 to 120,000 plaintiffs, inside and outside the MDL, to be eligible to participate in the settlement. That is the vast majority of current personal injury plaintiffs. Importantly, eligible claims include all six health endpoints that have been the focus of the litigation. Participating plaintiffs will sign broad releases of their claims and potential claims.

Kevin RhodesChief Legal Affairs Officer

Second, the agreement is structured to drive broad participation by setting plaintiff participation thresholds, with certain payments triggered upon reaching those thresholds. One threshold applies across all eligible plaintiffs, and a separate one applies to certain higher-risk claim types. As shown in the appendix, about $6.27 billion of the total settlement amount will be paid annually from 2028 to 2033 once those participation thresholds are met. If the eligible plaintiff participation percentage falls short of those thresholds, 3M has the right to walk away from the agreement, although we do not expect that to happen. I will note that this agreement includes no admission of liability, so if the thresholds are not met, 3M remains ready to continue defending itself in the litigation. Two additional payments within the overall settlement amount of $125 million each will be paid in 2029 and 2030 if participation reaches even higher levels.

Kevin RhodesChief Legal Affairs Officer

Finally, the agreement and the order we anticipate the MDL court will enter address remaining risks from plaintiffs who elect to continue to litigate and future personal injury claims inside and outside the MDL through several measures. First, we expect the court order will set forth evidentiary and timing requirements in the MDL for personal injury plaintiffs who don't settle and for future plaintiffs. Also, two additional payments of up to $50 million each in 2031 and 2032, also within the overall settlement amount, are contingent on our future docket. Finally, the agreement establishes a reserve fund of $680 million, not fully paid until 2034. Together, these provisions are designed to provide a framework for addressing both existing and future personal injury claims.

Kevin RhodesChief Legal Affairs Officer

Over the coming months, we will work with the parties and the MDL court to establish the settlement administration process, notify claimants, and confirm their participation. We will provide further details in our SEC filings as appropriate, and I refer you to our eight-K for the specific terms of the settlement agreement. With that, let me hand it to Anurag to cover the financial aspects of the agreement.

Anurag MaheshwariCFO

Thank you, Kevin. Turning to slide five, we believe the structure and financial terms of the agreement maintain our capital deployment flexibility. The agreement provides for a total nominal value of $7.35 billion, with payments spread over nine years. We will take a pre-tax charge of $5.8 billion, representing the present value of future payments, and consistent with our recent practice, the charge will be excluded from our non-GAAP results. Additional detail will be included in our SEC filings. The settlement, including the amounts and timing of the payments, is structured to align with 3M's other known obligations and at the same time preserve optionality for other capital priorities.

Anurag MaheshwariCFO

As shown in the appendix, the series of payments will start with $50 million in 2026, with no payment in 2027, and the remaining payments are spread across 2028 to 2034, with roughly 20% of the total falling in the final two years, 2033 and 2034. The combined cash payments to meet public water suppliers, Combat Arms, New Jersey, and personal injury settlement obligations step down every year from 2027 to 2034, and by the end of 2034, we will have paid down all of Combat Arms, personal injury, and virtually all of PWS. While the payments step down, we believe our free cash flow, expected to be $4.8 billion in 2026, will grow with earnings as we continue to execute on our strategic priorities.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day